Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA.
Department of Ophthalmology, Mayo Clinic, Rochester, MN.
Asia Pac J Ophthalmol (Phila). 2020 Mar-Apr;9(2):110-116. doi: 10.1097/APO.0000000000000274.
The aim of this study was to identify clinical factors predictive of time to central nervous system (CNS) lymphoma or death in patients with vitreoretinal lymphoma (VRL).
Retrospective cohort study.
Patients with VRL (n = 95 patients) from Januray 1, 1984 to July 30, 2018 were identified at a single ocular oncology center and records were retrospectively reviewed. Outcomes included Kaplan-Meier estimated time to CNS lymphoma and death.
There were 95 patients with VRL diagnosed at mean age 67 years, of which 70 patients had follow-up with the ocular oncology service. Mean time to CNS lymphoma in patients with isolated VRL was 56 months and did not differ by age, sex, bilateral ocular involvement, retinal infiltration, subretinal pigment epithelial (sub-RPE) infiltration, or treatment with prophylactic systemic chemotherapy (P > 0.05). Mean time to death was 66 months and did not differ when comparing those with CNS lymphoma diagnosed before VRL versus after VRL versus no CNS lymphoma at any time (67 vs 60 vs 64 months, P > 0.05). Presence of sub-RPE infiltration was associated with shorter mean time to death (46 vs 76 months, P = 0.04, odds ratio 1.9). Older patient age was associated with increased risk of death (odds ratio 1.0, P = 0.02). The mean time to death did not differ by sex, bilateral ocular involvement, retinal infiltration, timing of CNS or systemic lymphoma, or treatment with prophylactic systemic chemotherapy (P > 0.05).
Patients with VRL presenting with sub-RPE infiltration could have shorter mean survival time. Further studies are required to confirm these findings and determine whether sub-RPE infiltration is associated with more aggressive CNS lymphoma.
本研究旨在确定影响眼内淋巴瘤(VRL)患者中枢神经系统(CNS)淋巴瘤或死亡时间的临床因素。
回顾性队列研究。
在单一眼肿瘤中心,从 1984 年 1 月 1 日至 2018 年 7 月 30 日,共确定了 95 例 VRL 患者,对这些患者的记录进行了回顾性审查。主要研究结果包括 CNS 淋巴瘤和死亡的 Kaplan-Meier 估计时间。
95 例 VRL 患者的平均年龄为 67 岁,其中 70 例在眼肿瘤学服务处进行了随访。孤立性 VRL 患者的 CNS 淋巴瘤平均发生时间为 56 个月,年龄、性别、双眼受累、视网膜浸润、视网膜下色素上皮(sub-RPE)浸润、或预防性全身化疗(P>0.05)对其无影响。中位死亡时间为 66 个月,比较 CNS 淋巴瘤诊断时间早于、晚于、或始终未出现 VRL 的患者的中位死亡时间无差异(67、60、64 个月,P>0.05)。存在 sub-RPE 浸润与较短的中位死亡时间相关(46 与 76 个月,P=0.04,优势比 1.9)。老年患者的死亡风险较高(优势比 1.0,P=0.02)。患者的性别、双眼受累、视网膜浸润、CNS 或全身淋巴瘤的发病时间以及预防性全身化疗的应用与死亡时间无关(P>0.05)。
患有 VRL 且存在 sub-RPE 浸润的患者的平均生存时间可能更短。需要进一步的研究来证实这些发现,并确定 sub-RPE 浸润是否与更具侵袭性的 CNS 淋巴瘤相关。